Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Stocks to Buy for the Long Term. According to a report by ...

U.S. drugmaker Eli Lilly and Company signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the ...

Researchers developed a topical gene therapy that corrects disease-causing mutations in human skin models using lipid ...

Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU. Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013 ...

The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge ...

Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...

Scientists achieved a genetic breakthrough by removing an extra human chromosome using gene-editing technology. This landmark study successfully deleted the surplus chromosome 21 responsible for Down ...

After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs ...

Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively ...

CRISPR gene editing has transitioned from a laboratory curiosity to a cornerstone of modern biotechnology, revolutionizing our approach to genetic diseases, including Charcot-Marie-Tooth (CMT) disease ...

Chinese scientist He Jiankui wants to end Alzheimer’s and thinks Silicon Valley is conducting a “Nazi eugenic experiment.” ...